Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Ron Sigourney who wrote (4936)	7/16/1998 6:43:00 PM
From: Linda Kaplan	Respond to of 7041

Ron: That's one of the largest pharmacies in Mexico, and internet presence, and they DO stock Vasomax, as opposed to the one that Myron cited, which doesn't even stock the drug. If you want updated information from them, do some research and call them yourself. It's your turn to do some work. You've contributed ZERO to this thread in all the time I've read it. Only insults and slurs. Do something constructive to defend or preserve your financial position in this stock. Let's see you offer some factual information instead of attacks and insults. Call that pharmacy or one of equal stature and get the sales information. Find out what they pay for the drug, what they sell it for, the sales figures and get the same info on Viagra. Do a comparison for all to see. I'll be happy to have an update. YOU get it, but get it from a place I can verify it. NOT made up lies like Myron Kor posted. I understand you are long this stock and don't like people who are critical of the company. But you'd probably better preserve your finances if you did some actual research on the subject, rather than just coming around here to attack me. Linda

To: Ron Sigourney who wrote (4936)	7/20/1998 10:42:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 7041

The amazing Matt Geller - Oppenheimer analyst Much has been made about CIBC-Oppenheimer "analyst" Matt Geller's positive comments about Zonagen. Quite frankly, my parakeet is more qualified to analyze biotech companies than Mr. Geller. Mr. Geller belongs to that growing cadre of "analysts" that will always find some way to put a positive spin on even the most obvious scams. Mr. Geller's spotty and biased research should give investors pause before lending much credence to anything he says. In early April, Cor Therapeutics shot up on News of limited FDA approval of Integrelin (new indication). Mr. Geller immediately issued an upgrade (to "strong buy") as the stock rose from the low teens to the low twenties. Mr. Geller then set a $30 price target by the "end of the year". healthcarenewsserver.com What Mr. Geller conveniently neglected to do - much to the dismay of small investors who bought Corr at grossly inflated prices- was to mention the extremely limited market of Integrelin, even with the new indication. There was no way Cor could justify its market cap at those levels. Sure enough, the stock marched back down to the low teens (check a chart of CORR from early April to present). Mr. Geller's analysis of Zonagen is incorrect, and should be viewed with a great deal of skepticism by the small investor. Research material about Phentolamine and Zonagen's past shady activities - including the Immumax fraud, and its odd relationships with TXB and ARNX, are publicly available and should be studied carefully.